An interventional study of Melatonin and nitric oxide generator in Congenital Peumonia, Persistent Pulmonary Hypertension of Newborn and Congenital Diaphragmatic Hernia, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study
Neonates fulfilling the inclusion criteria will be divided into 2 groups:
Intervention group(26 Neonates) will receive iNO and melatonin
iNO
In case of failure of either group, patient will receive rescue treatment as milrinone at a dose 0.375 µg/kg/min to a maximum 0.750 µg/kg/min intravenous infusion
Study Tools : All of the following data will be obtained:
Management in NICU:
ECHO: It will be done before starting therapy, after 24 hours and after completing the treatment
Monitoring of complications:
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
This study's planned enrollment of 52 is above the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.
Browse Persistent Fetal Circulation Syndrome studies →Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
Control group (26Neonates) gestational age and weight matched to the intervention group and will receive only iNO will be initiated at 20 ppm without melatonin The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy. If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued
Device: nitric oxide generator
Intervention group (26Neonates) will receive iNO and melatonin. melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
Drug: Melatonin · Device: nitric oxide generator
Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
iNO will be initiated at 20 ppm. The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued
melatonin as an adjuvant therapy to iNO
1. oxygen saturation % every 3hrs 2. Fraction of inspired oxygen (FiO2) % which will all be measured at baseline (just before iNO administration) and at pre-specified intervals (15, 30, 45, and 60 min) after iNO then every 3hours through the course of study.
Time frame: 72 hours
effect of iNO and melatonin on cerebral perfusion.
Serum S100B will be measured 24 hours after diagnosis cut off value (≥ 0.10 µg/L) .
Time frame: 24 hours
Effect of iNO and Melatonin on cerebral perfusion
middle cerebral artery resistive index will be measured before and after starting therapy cutoff value 0.67-0.68
Time frame: 72 hours
Effect of iNO and Melatonin on electroencephalogram
Burdjalov score before starting treatment during study after completion of therapy. a total ranging from 0 to 13, with higher values indicating a more mature and better organized background.
Time frame: 72 hours
Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
Persistent Fetal Circulation Syndrome →